Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280


Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A.

Cancer Res. 2004 Dec 15;64(24):9105-14.


Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.

Cancer Res. 2004 Jul 15;64(14):4900-5.


Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.

Wang S, El-Deiry WS.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15095-100. Epub 2003 Nov 26.


Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.

Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.

Cancer Res. 2006 May 15;66(10):5363-70.


Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.

Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E.

Oncogene. 2002 May 16;21(22):3611-9.


Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.

Nat Med. 2002 Mar;8(3):274-81.


Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.

Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.

Cancer Res. 2006 Jun 1;66(11):5867-74.


CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.

Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M.

Oncogene. 2001 Jul 12;20(31):4128-37.


Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.

Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL.

Oncology. 2008;74(3-4):188-97. doi: 10.1159/000151366. Epub 2008 Aug 20.

Supplemental Content

Support Center